

Presentation No.	Presentation Title	Chair/Speaker's Name	Affiliation
FACO Poster Session 1 * This is not charging session.			
FP1-1	Who will benefit from primary tumor surgery: A prediction model-based analysis of patients with metastatic breast cancer	Wen Zhao	Breast Cancer, Department of Clinical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, China
FP1-2	In vivo isolation of circulating tumour cells using CellCollector and detection of gene mutations in different metastasis organ sites in breast cancer	Sainan Li	Department of Breast Oncology, Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, China
FP1-3	The dynamic changes of the epithelial and mesenchymal composition of circulating tumor cells in breast cancer patients treated with Neo-adjuvant Chemotherapy	Zhao Liu	Departement of Thyroid and Breast Surgery, The Affiliated Hospital of Xuzhou Medical University, China/Departement of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, China
FP1-4	Preparation and evaluation study of Cy754-Rituximab: A new receptor-targeted tracer for sentinel lymph node in animal model	Binbin Cong	Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University, China
FP1-5	The study of lymphatic drainage pattern of internal mammary sentinel lymph node in breast	Xiaoshan Cao	Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University, China
FP1-6	Identification and integrated analysis of differentially expressed CircRNAs reveal a potential Hsa_circ_0087378-miR-1260b-SFRP1 regulatory axis in ER-positive subtype breast cancer	Chenwei Yuan	Department of Breast Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, China
FP1-7	Discussion on indications of internal mammary sentinel lymph node biopsy in breast cancer in the era of precision medicine	Pengfei Qiu	Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University, China
FP1-8	Breast cancer radiotherapy in China: A multicenter 5-year (2012-2016) study based on a cross-sectional investigation and questionnaire survey	Dan Ou	Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China
FP1-9	Upfront intracranial radiotherapy may improve survival for unfavorable prognostic breast cancer brain metastasis patients with Breast-GPA 0-2.0	Dan Ou	Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China
FP1-10	(Withdrawn)		
FP1-11	Multi-clonal mutation signatures in primary breast cancer and axillary lymph node metastases	Xin Wang	Department of Breast Surgical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
FP1-12	A small percentage of primary breast cancer shows high tumor mutation burden and may benefit from immune checkpoint inhibitor therapy	Jingshu Wang	Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China
FP1-13	Characterization of FGFR1/2 genetic alterations reveals novel fusions of FGFR1 in Chinese breast cancer	Yulei Wang	Department of Breast Cancer, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China
FP1-14	Pyrotinib overcomes trastuzumab resistance in HER2 amplified breast cancer	Kai Zhang	Medical Department, Sun Yat-Sen University Cancer Center, China
FP1-15	CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER-2-positive breast cancer	Kai Zhang	Medical Department, Sun Yat-Sen University Cancer Center, China
FP1-16	M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways	Yizhuo Wang	Department of Cancer Center, First Hospital of Jilin University, China
FP1-17	Efficacy of adjuvant chemotherapy regimens with or without oxaliplatin in intestinal and diffuse type pathological stage III gastric cancer after D2 gastrectomy	Xi Cheng	Department of Medical Oncology, Zhongshan Hospital Fudan University, China
FP1-18	Clinical efficacy of combination intravenous and intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis	Sheng Yang	Medical Oncology, Fujian Medical University Union Hospital, China/Teaching and Research Department of Oncology, Union Clinical Medical College of Fujian Medical University, China/Fujian Provincial Key Laboratory of Translational Cancer Medicine, China
FP1-19	How to improve the lymph node detection and staging accuracy in gastric cancer patients? A randomized controlled trial in single center	Yao Zengwu	Gastrointestinal Surgery Ward I, Yantai Yuhuangding Hospital, the Affiliated Hospital of Qingdao University, China

Presentation No.	Presentation Title	Chair/Speaker's Name	Affiliation
FP1-20	Effectiveness and safety of Apatinib combined with SOX regimen for conversion therapy of initial unresectable cT4bN1-N3M0 advanced gastric cancer.	Yao Zengwu	Gastrointestinal Surgery Ward I, Yantai Yuhuangding Hospital, the Affiliated Hospital of Qingdao University, China
FP1-21	The effect of Enhanced Recovery After Surgery (ERAS) and standardization antimicrobial prophylaxis on postoperative intestinal function recovery and microbiota in gastroectomy: a prospective study	Yao Zengwu	Gastrointestinal Surgery Ward I, Yantai Yuhuangding Hospital, the Affiliated Hospital of Qingdao University, China
FP1-22	To explore the consistency of double wax block in the HER-2 gastric cancer biopsy and surgical specimens	Li Yuanliang	Pathology Department, Yunnan Province Cancer Hospital Pathology Department of China, Kunming Medical University, China
FP1-23	Long- versus short-interval follow-up after resection of hepatocellular carcinoma: a retrospective cohort study	He Wei	Department of Hepatobiliary Oncology, Sun Yat-Sen University Cancer Center, China
FP1-24	Nomogram to predict survival of patients with recurrence of hepatocellular carcinoma after surgery	He Wei	Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, China
FP1-25	A panel of genes identified as targets for 8q24.13-24.3 gain contributing to unfavorable overall survival in patients with hepatocellular carcinoma	Kun Zhao	Department of Oncology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, China/Shanghai Clinical College of Anhui Medical University, China
FP1-26	Radiofrequency ablation versus laparoscopic hepatectomy for hepatocellular carcinoma:a propensity score matching study	Yangxun Pan	Department of Hepatobiliary & Pancreatic Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, China
FP1-27	Acute bile duct necrosis with bilioma formation after DEB-TACE in patient with liver malignant tumor	Caoye Wang	Interventional Oncology, Interventional Radiology Department, First People's Hospital of Changzhou, China
FP1-28	USP10 suppresses tumor progression by stabilizing PTEN and AMPKa in hepatocellular carcinoma cells	Chang Lu	Department of Hepatobiliary Surgery, 1st Affiliated Hospital of Dalian Medical University, China/scientific reasearch center for translational medicine, Dalian Institute of Chemical Physics Chinese Academy of Sciences, China
FP1-29	The effect of selective c-MET inhibitor on HCC in the MET-active, beita-catenin mutated mouse model	Zhan Na	Division of Experimental Pathology, Department of Pathology, University of Pittsburgh School of Medicine, China/Department of Pathology, Renmin Hospital of Wuhan University, China/Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh School of Medicine, USA
FP1-30	Bronchobiliary fistula after multiple transcatheter arterial chemoembolizations for hepatocellular carcinoma: A case report	Caoye Wang	Interventional Oncology, Interventional Radiology Department, First People's Hospital of Changzhou, China
FP1-31	The role and mechanism of Mir-1269a on the targeted regulation of HOXD10 in invasion of cholangiocarcinoma cells (CCC)	Yang Haixia	Radiotherapy, The Second Affiliated Hospital, Air Force Medical University, China
FP1-32	The antitumor effects of Apatinib on pancreatic cancer cells and subcutaneous xenograft tumor in nude mice	Yuan Hu	The First Affiliated Hospital of Xi'an Jiaotong University, Department of Oncology, University of Xi'an Jiaotong, China
FP1-33	Adjuvant therapy of S-1 or gemcitabine in resected pancreatic cancer: A cost-effectiveness analysis based on JASPAC-01 trial	Weiting Liao	Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, China/West China Biomedical Big Data Center, Sichuan University, China, China
FP1-34	IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway	Sun Longhao	Department of General Surgery, Tianjin Medical University General Hospital, China/Department of Cancer Biology, Comprehensive Cancer Center of Wake Forest Baptist Medical Center, China/Department of Pathology, The University of Texas MD Anderson Cancer Center, USA